How important is play?

Would you ever consider playing in a bomb site?

Ascendis Pharma Reports Third Quarter 2025 Financial Results

Q3 2025 revenue of €143.1 million for YORVIPATH® and €50.7 million for SKYTROFA® - Q3 2025 operating profit of €11.0 million - TransCon® CNP (navepegritide) under FDA Priority Review for the ...